论文部分内容阅读
目的 :探讨血清可溶性白细胞介素 2受体 (SIL -2 )的表达水平与非小细胞肺癌患者 (NSCLC)病期和预后的关系。方法 :对 50例非小细胞肺癌患者 (NSCLC)手术前 ,术后 10d和术后 30d血清SIL -2R水平进行了动态研究。采用酶标双抗体夹心法测SIL -2R水平。结果 :NSCLC患者SIL -2R表达水平明显高于正常人 ,P <0 0 0 1。未复发组的患者术后SIL -2R表达水平呈现一个暂时性增高到逐渐下降近正常 ,表明其术后免疫功能从暂时抑制到逐渐恢复的过程。复发组的患者术后SIL -2R表达水平持续居高不下 ,表明其术后免疫功能持续低下。结论 :未复发组与复发组比较P <0 0 0 1,提示SIL -2R表达水平与NSCLC患者的病期和预后有密切关系
Objective: To investigate the relationship between serum soluble interleukin-2 receptor (SIL-2) expression and the non-small cell lung cancer (NSCLC) stage and prognosis. Methods: Serum levels of SIL-2R in 50 non-small cell lung cancer patients (NSCLC) before surgery, 10 days and 30 days after surgery were studied. The level of SIL -2R was measured by ELISA double antibody sandwich method. Results: The expression of SIL-2R in NSCLC patients was significantly higher than that in normal controls (P <0.01). The level of SIL-2R expression in patients with non-recurrent group showed a transient increase to a gradual decrease near normal, indicating that the postoperative immune function from the temporary inhibition to the gradual recovery process. The level of SIL-2R expression in postoperative recurrence patients remained high, indicating that the postoperative immune function continued to be low. Conclusion: There is a significant difference between the non-recurrent group and the recurrent group (P <0.01), suggesting that the level of SIL-2R expression is closely related to the stage and prognosis of patients with NSCLC